Aardvark Therapeutics Faces Class Action Over ARD-101 Safety Claims
Investors in Aardvark Therapeutics have until October 13, 2026, to file as lead plaintiffs in a class action lawsuit against the biopharmaceutical company. The litigation alleges that the firm misled shareholders regarding the safety and commercial viability of its lead drug candidate, ARD-101, following a series of clinical setbacks.
























